ELTX · NASDAQ · Biotechnology

Elicio Therapeutics

Develops AMP-enabled cancer immunotherapies centered on the ELI-002 mutant-KRAS program.

$2.80
Pre-market+0.10 (+3.51%)
At close$2.71(−4.75%)

Something off on this page? Send us feedback.

Next report
Nov 12, 2026
estimated · in 72 days
EPS estimate
−$0.52
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$1.02−$0.87−$0.66−$0.60−$0.49−$0.65−$0.43Pending
Estimate−$0.94−$0.67−$0.69−$0.62−$0.47−$0.49−$0.54−$0.52
Surprise−8.5%−29.9%+4.3%+3.2%−4.3%−32.7%+20.0%

RevenueReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$1.2MPending
Estimate
Surprise

History

DateEstimateReportedSurprise
Nov 2026−$0.52
Aug 2026−$0.54−$0.43+20.0%
May 2026−$0.49−$0.65−32.7%
Mar 2026−$0.47−$0.49−4.3%
Nov 2025−$0.62−$0.60+3.2%

The latest year is open to everyone — the 23 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Feb 2024
Nov 2023
Aug 2023
May 2023
Dec 2022
Sep 2022
Jun 2022
Mar 2022
Dec 2021
Sep 2021
Jun 2021
Mar 2021
Dec 2020
Sep 2020
Jun 2020
Mar 2020
Dec 2019
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 12, 2026−$0.52
Aug 13, 2026−$0.54−$0.43+20.0%−1.9%
May 11, 2026−$0.49−$0.65−32.7%−9.1%
Mar 12, 2026−$0.47−$0.49−4.3%+11.9%
Nov 13, 2025−$0.62−$0.60+3.2%−2.2%

The latest year is open to everyone — the 23 quarters behind it read with an account.

Sign in
Aug 7, 2025
May 13, 2025
Mar 31, 2025
Nov 13, 2024
Aug 13, 2024
May 15, 2024
Feb 13, 2024
Nov 9, 2023
Aug 11, 2023
May 10, 2023
Dec 31, 2022
Sep 30, 2022
Jun 30, 2022
Mar 31, 2022
Dec 31, 2021
Sep 29, 2021
Jun 30, 2021
Mar 31, 2021
Dec 31, 2020
Sep 30, 2020
Jun 30, 2020
Mar 31, 2020
Dec 31, 2019